Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 340732, 10 pages
http://dx.doi.org/10.1155/2015/340732
Review Article

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer

1Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Shengli Road, North District, Tainan City 704, Taiwan
2Institute of Oral Medicine, College of Medicine, National Cheng Kung University, No. 1, University Road, East District, Tainan City 704, Taiwan
3UCLA School of Dentistry, 10833 Le Conte, CHS-Box 951668, Los Angeles, CA 90095-1668, USA
4Institute of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 35, Xiaodong Road, North District, Tainan City 704, Taiwan

Received 29 January 2015; Accepted 18 March 2015

Academic Editor: Aurelio Ariza

Copyright © 2015 Wei-Lun Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. “Targeting resistance in lung cancer,” Cancer Discovery, vol. 3, no. 12, article OF9, 2013. View at Publisher · View at Google Scholar
  3. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. L. A. Diaz Jr. and A. Bardelli, “Liquid biopsies: genotyping circulating tumor DNA,” Journal of Clinical Oncology, vol. 32, no. 6, pp. 579–586, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. F.-C. Bidard, B. Weigelt, and J. S. Reis-Filho, “Going with the flow: from circulating tumor cells to DNA,” Science Translational Medicine, vol. 5, no. 207, p. 207ps14, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. S. Wicha and D. F. Hayes, “Circulating tumor cells: not all detected cells are bad and not all bad cells are detected,” Journal of Clinical Oncology, vol. 29, no. 12, pp. 1508–1511, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Mandel and P. Metais, “Les acides nucleiques du plasma sanguin chez l'homme,” Comptes Rendus des Séances de la Société de Biologie et de ses Filiales, vol. 142, no. 3-4, pp. 241–243, 1948. View at Google Scholar
  8. S. A. Leon, B. Shapiro, D. M. Sklaroff, and M. J. Yaros, “Free DNA in the serum of cancer patients and the effect of therapy,” Cancer Research, vol. 37, no. 3, pp. 646–650, 1977. View at Google Scholar · View at Scopus
  9. H. Schwarzenbach, D. S. B. Hoon, and K. Pantel, “Cell-free nucleic acids as biomarkers in cancer patients,” Nature Reviews Cancer, vol. 11, no. 6, pp. 426–437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Stroun, J. Lyautey, C. Lederrey, A. Olson-Sand, and P. Anker, “About the possible origin and mechanism of circulating DNA: apoptosis and active DNA release,” Clinica Chimica Acta, vol. 313, no. 1-2, pp. 139–142, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Raposo and W. Stoorvogel, “Extracellular vesicles: exosomes, microvesicles, and friends,” The Journal of Cell Biology, vol. 200, no. 4, pp. 373–383, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Guescini, D. Guidolin, L. Vallorani et al., “C2C12 myoblasts release micro-vesicles containing mtDNA and proteins involved in signal transduction,” Experimental Cell Research, vol. 316, no. 12, pp. 1977–1984, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Kahlert, S. A. Melo, A. Protopopov et al., “Identification of double-stranded genomic dna spanning all chromosomes with mutated KRAS and P53 DNA in the serum exosomes of patients with pancreatic cancer,” The Journal of Biological Chemistry, vol. 289, no. 7, pp. 3869–3875, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. B. K. Thakur, H. Zhang, A. Becker et al., “Double-stranded DNA in exosomes: a novel biomarker in cancer detection,” Cell Research, vol. 24, no. 6, pp. 766–769, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. D. D. Taylor and C. Gercel-Taylor, “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer,” Gynecologic Oncology, vol. 110, no. 1, pp. 13–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Duijvesz, T. Luider, C. H. Bangma, and G. Jenster, “Exosomes as biomarker treasure chests for prostate cancer,” European Urology, vol. 59, no. 5, pp. 823–831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. C. R. Newton, A. Graham, L. E. Heptinstall et al., “Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS),” Nucleic Acids Research, vol. 17, no. 7, pp. 2503–2516, 1989. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Whitcombe, J. Theaker, S. P. Guy, T. Brown, and S. Little, “Detection of PCR products using self-probing amplicons and fluorescence,” Nature Biotechnology, vol. 17, no. 8, pp. 804–807, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Kuang, A. Rogers, B. Y. Yeap et al., “Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer,” Clinical Cancer Research, vol. 15, no. 8, pp. 2630–2636, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Wang, X. Han, X. Hu et al., “Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients,” Clinica Chimica Acta, vol. 430, pp. 63–70, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. X. Liu, Y. Lu, G. Zhu et al., “The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies,” Journal of Clinical Pathology, vol. 66, no. 12, pp. 1065–1069, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Goto, Y. Ichinose, Y. Ohe et al., “Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer,” Journal of Thoracic Oncology, vol. 7, no. 1, pp. 115–121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Kimura, M. Suminoe, K. Kasahara et al., “Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA),” British Journal of Cancer, vol. 97, no. 6, pp. 778–784, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Kimura, K. Kasahara, M. Kawaishi et al., “Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer,” Clinical Cancer Research, vol. 12, no. 13, pp. 3915–3921, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Xu, J. Wu, C. Xue et al., “Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib,” OncoTargets and Therapy, vol. 5, pp. 439–447, 2012. View at Google Scholar
  26. G. Pohl and L.-M. Shih, “Principle and applications of digital PCR,” Expert Review of Molecular Diagnostics, vol. 4, no. 1, pp. 41–47, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Vogelstein and K. W. Kinzler, “Digital PCR,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 16, pp. 9236–9241, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. T. K. F. Yung, K. C. A. Chan, T. S. K. Mok, J. Tong, K.-F. To, and Y. M. D. Lo, “Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients,” Clinical Cancer Research, vol. 15, no. 6, pp. 2076–2084, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Kahn, W. Jiang, T. A. Culbertson, I. B. Weinstein, G. M. Williams, and N. Z. Tomita Ronai, “Rapid and sensitive nonradioactive detection of mutant K-ras genes via ’enriched‘ PCR amplification,” Oncogene, vol. 6, no. 6, pp. 1079–1083, 1991. View at Google Scholar · View at Scopus
  30. H. Asano, S. Toyooka, M. Tokumo et al., “Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay,” Clinical Cancer Research, vol. 12, no. 1, pp. 43–48, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Zhao, R.-B. Han, J. Zhao et al., “Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients,” Respiration, vol. 85, no. 2, pp. 119–125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Jiang, F. Liu, L. Yang et al., “Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer,” Journal of International Medical Research, vol. 39, no. 4, pp. 1392–1401, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. C. He, M. Liu, C. Zhou et al., “Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer,” International Journal of Cancer, vol. 125, no. 10, pp. 2393–2399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Ray and B. Nordén, “Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future,” The FASEB Journal, vol. 14, no. 9, pp. 1041–1060, 2000. View at Google Scholar · View at Scopus
  35. P. Wittung, P. E. Nielsen, O. Buchardt, M. Egholm, and B. Nordén, “DNA-like double helix formed by peptide nucleic acid,” Nature, vol. 368, no. 6471, pp. 561–563, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. C.-C. Chiou, J.-D. Luo, and T.-L. Chen, “Single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe for the detection of rare mutations,” Nature Protocols, vol. 1, no. 6, pp. 2604–2612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. L. A. Ugozzoli, D. Latorra, R. Pucket, K. Arar, and K. Hamby, “Real-time genotyping with oligonucleotide probes containing locked nucleic acids,” Analytical Biochemistry, vol. 324, no. 1, pp. 143–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Obradovic and V. Jurisic, “Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patients,” Multidisciplinary Respiratory Medicine, vol. 7, no. 7, article 52, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Nagai, H. Miyazawa, T. Tanaka et al., “Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp,” Cancer Research, vol. 65, no. 16, pp. 7276–7282, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Tanaka, Y. Nagai, H. Miyazawa et al., “Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers,” Cancer Science, vol. 98, no. 2, pp. 246–252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Sutani, Y. Nagai, K. Udagawa et al., “Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp,” British Journal of Cancer, vol. 95, no. 11, pp. 1483–1489, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. H.-R. Kim, S. Y. Lee, D.-S. Hyun et al., “Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping,” Journal of Experimental & Clinical Cancer Research, vol. 32, no. 1, article 50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. S. T. Kim, J. S. Sung, U. H. Jo, K. H. Park, S. W. Shin, and Y. H. Kim, “Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?” Medical Oncology, vol. 30, no. 1, article 328, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. D. Dressman, H. Yan, G. Traverso, K. W. Kinzler, and B. Vogelstein, “Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8817–8822, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Diehl, K. Schmidt, K. H. Durkee et al., “Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients,” Gastroenterology, vol. 135, no. 2, pp. 489.e7–498.e7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Lauring and B. H. Park, “BEAMing sheds light on drug resistance,” Clinical Cancer Research, vol. 17, no. 24, pp. 7508–7510, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. A. L. Richardson and J. D. Iglehart, “BEAMing up personalized medicine: mutation detection in blood,” Clinical Cancer Research, vol. 18, no. 12, pp. 3209–3211, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Taniguchi, J. Uchida, K. Nishino et al., “Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas,” Clinical Cancer Research, vol. 17, no. 24, pp. 7808–7815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Ding, R. W. K. Chiu, T. K. Lau et al., “MS analysis of single-nucleotide differences in circulating nucleic acids: application to noninvasive prenatal diagnosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 29, pp. 10762–10767, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. K. Sakai, A. Horiike, D. L. Irwin et al., “Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor,” Cancer Science, vol. 104, no. 9, pp. 1198–1204, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Brevet, M. L. Johnson, C. G. Azzoli, and M. Ladanyi, “Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors,” Lung Cancer, vol. 73, no. 1, pp. 96–102, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Hu, X. Liu, Y. Chen et al., “Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis,” Oncology Reports, vol. 28, no. 5, pp. 1815–1821, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. C. F. Taylor, “Mutation scanning using high-resolution melting,” Biochemical Society Transactions, vol. 37, no. 2, pp. 433–437, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Keller, A. Hartmann, J. Mueller, and H. Höfler, “Denaturing high pressure liquid chromatography (DHPLC) for the analysis of somatic p53 mutations,” Laboratory Investigation, vol. 81, no. 12, pp. 1735–1737, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. P. A. Jänne, A. M. Borras, Y. Kuang et al., “A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening,” Clinical Cancer Research, vol. 12, no. 3, pp. 751–758, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. V. Cohen, J. S. Agulnik, J. Jarry et al., “Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer,” Cancer, vol. 107, no. 12, pp. 2858–2865, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Bai, L. Mao, H. S. Wang et al., “Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2653–2659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. T. M. Chin, D. Anuar, R. Soo et al., “Detection of epidermal growth factor receptor variations by partially denaturing HPLC,” Clinical Chemistry, vol. 53, no. 1, pp. 62–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. E. R. Mardis, “Next-generation sequencing platforms,” Annual Review of Analytical Chemistry, vol. 6, pp. 287–303, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. M. L. Metzker, “Sequencing technologies the next generation,” Nature Reviews Genetics, vol. 11, no. 1, pp. 31–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. H. L. Rehm, “Disease-targeted sequencing: a cornerstone in the clinic,” Nature Reviews Genetics, vol. 14, no. 4, pp. 295–300, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. J. C. Mwenifumbo and M. A. Marra, “Cancer genome-sequencing study design,” Nature Reviews Genetics, vol. 14, no. 5, pp. 321–332, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. M. T. Lin, S. L. Mosier, M. Thiess et al., “Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing,” American Journal of Clinical Pathology, vol. 141, no. 6, pp. 856–866, 2014. View at Publisher · View at Google Scholar
  64. D. de Biase, M. Visani, U. Malapelle et al., “Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy),” PLoS ONE, vol. 8, no. 12, Article ID e83607, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. H. S. Kim, J. S. Sung, S.-J. Yang et al., “Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma,” PLoS ONE, vol. 8, no. 12, Article ID e81975, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Kukita, J. Uchida, S. Oba et al., “Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data,” PLoS ONE, vol. 8, no. 11, Article ID e81468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Couraud, F. Vaca-Paniagua, S. Villar et al., “Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002,” Clinical Cancer Research, vol. 20, no. 17, pp. 4613–4624, 2014. View at Publisher · View at Google Scholar
  68. V. Casadio, D. Calistri, S. Salvi et al., “Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study,” BioMed Research International, vol. 2013, Article ID 270457, 5 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. V. Casadio, D. Calistri, M. Tebaldi et al., “Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data,” Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 8, pp. 1744–1750, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. S. H. Zhang, S. M. Zhao, Z. M. Zhao, and C. T. Li, “Genotyping of urinary samples stored with EDTA for forensic applications,” Genetics and Molecular Research, vol. 11, no. 3, pp. 3007–3012, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. D. M. Hyman, E. L. Diamond, C. R. Vibat et al., “Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders,” Cancer Discovery, vol. 5, no. 1, pp. 64–71, 2015. View at Publisher · View at Google Scholar
  72. F. Janku, C. R. T. Vibat, G. S. Falchook et al., “Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers,” ASCO Annual Meeting, abstract e22175, 2014. View at Google Scholar
  73. K. C. A. Chan, S.-W. Yeung, W.-B. Lui, T. H. Rainer, and Y. M. D. Lo, “Effects of preanalytical factors on the molecular size of cell-free DNA in blood,” Clinical Chemistry, vol. 51, no. 4, pp. 781–784, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. P. Denny, F. K. Hagen, M. Hardt et al., “The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions,” Journal of Proteome Research, vol. 7, no. 5, pp. 1994–2006, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. N. Spielmann and D. Wong, “Saliva: diagnostics and therapeutic perspectives,” Oral Diseases, vol. 17, no. 4, pp. 345–354, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. T. Rylander-Rudqvist, N. Håkansson, G. Tybring, and A. Wolk, “Quality and quantity of saliva DNA obtained from the self-administrated oragene method—a pilot study on the cohort of Swedish men,” Cancer Epidemiology, Biomarkers & Prevention, vol. 15, no. 9, pp. 1742–1745, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. M.-L. Looi, H. Zakaria, J. Osman, and R. Jamal, “Quantity and quality assessment of DNA extracted from saliva and blood,” Clinical Laboratory, vol. 58, no. 3-4, pp. 307–312, 2012. View at Google Scholar · View at Scopus
  78. T. V. O. Hansen, M. K. Simonsen, F. C. Nielsen, and Y. A. Hundrup, “Collection of blood, saliva, and buccal cell samples in a pilot study on the Danish nurse cohort: comparison of the response rate and quality of genomic DNA,” Cancer Epidemiology Biomarkers and Prevention, vol. 16, no. 10, pp. 2072–2076, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. N. J. Bonne and D. T. W. Wong, “Salivary biomarker development using genomic, proteomic and metabolomic approaches,” Genome Medicine, vol. 4, no. 10, article 82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. F. Wei, C. Lin, A. Joon et al., “Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer,” The American Journal of Respiratory and Critical Care Medicine, vol. 190, no. 10, pp. 1117–1126, 2014. View at Publisher · View at Google Scholar
  81. J. Luo, L. Shen, and D. Zheng, “Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis,” Scientific Reports, vol. 4, article 6269, 2014. View at Publisher · View at Google Scholar
  82. S. Kobayashi, T. J. Boggon, T. Dayaram et al., “EGFR mutation and resistance of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 352, no. 8, pp. 786–792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. W. Pao, V. A. Miller, K. A. Politi et al., “Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain,” PLoS Medicine, vol. 2, no. 3, article e73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  84. R. K. Thomas, H. Greulich, Y. Yuza et al., “Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors,” Cold Spring Harbor Symposia on Quantitative Biology, vol. 70, pp. 73–81, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. K. Taniguchi, J. Uchida, K. Nishino et al., “Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas,” Clinical Cancer Research, vol. 17, no. 24, pp. 7808–7815, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. D. R. Aberle, A. M. Adams, C. D. Berg et al., “Reduced lung-cancer mortality with low-dose computed tomographic screening,” The New England Journal of Medicine, vol. 365, no. 5, pp. 395–409, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. K. Courtright and S. Manaker, “Counterpoint: should lung cancer screening by chest CT scan be a covered benefit? No,” Chest, vol. 147, no. 2, pp. 289–292, 2015. View at Publisher · View at Google Scholar
  88. A. M. Newman, S. V. Bratman, J. To et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage,” Nature Medicine, vol. 20, no. 5, pp. 548–554, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. X. Zhang, Y. L. Wu, J. Wang et al., “A prospective comparison study on EGFR mutations by direct sequencing and ARMS in completely resected Chinese non-small cell lung cancer with adenocarcinoma histology (ICAN),” in Proceedings of the ASCO Annual Meeting, European Society for Medical Oncology, 2014.
  90. Y. Shi, J. S.-K. Au, S. Thongprasert et al., “A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER),” Journal of Thoracic Oncology, vol. 9, no. 2, pp. 154–162, 2014. View at Publisher · View at Google Scholar · View at Scopus